Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PLUR

Pluri Inc

Dec 11 • 04:00PM ET

5.04

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • Israel • NASD

Peers: AAPL GOOGL MSFT AMZN TSLA META NVDA NFLX ORCL INTC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.10	Insider Own	33.27%	Shs Outstand	5.51M	Perf Week	1.27%
Market Cap	28.03M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.71M	Perf Month	-1.12%
Income	-21.81M	PEG	-	EPS next Q	-	Inst Own	6.14%	Short Float	0.23%	Perf Quarter	0.26%
Sales	0.60M	P/S	46.72	EPS this Y	-	Inst Trans	-2.94%	Short Ratio	0.33	Perf Half Y	-10.27%
Book/sh	-0.96	P/B	-	EPS next Y	-	ROA	-54.53%	Short Interest	0.01M	Perf Year	5.06%
Cash/sh	4.68	P/C	1.08	EPS next 5Y	-	ROE	-1205.58%	52W Range	3.77 - 8.48	Perf YTD	8.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.51%	ROI	-87.17%	52W High	-40.53%	Beta	1.63
Dividend TTM	-	Quick Ratio	5.90	Sales past 5Y	-24.23%	Gross Margin	36.29%	52W Low	33.67%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	5.90	EPS Y/Y TTM	28.10%	Oper. Margin	-3675.42%	RSI (14)	47.85	Volatility	6.51% 8.63%
Employees	118	Debt/Eq	-	Sales Y/Y TTM	135.43%	Profit Margin	-3646.99%	Recom	3.00	Target Price	24.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-12.21%	Payout	-	Rel Volume	0.00	Prev Close	5.04
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	503.70%	Earnings	-	Avg Volume	25.58K	Price	5.04
SMA20	-3.95%	SMA50	0.84%	SMA200	-10.67%	Trades		Volume	0	Change	0.00%

Dec-09-24 09:00AM	Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESSWIRE)
Nov-25-24 08:30AM	Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns (GlobeNewswire) +7.55%
Nov-12-24 05:52PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +8.43% +9.22%
01:00PM	Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
06:00AM	Loading…
Nov-11-24 06:00AM	BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing (PR Newswire) +11.92%
Oct-28-24 07:00AM	Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority (GlobeNewswire)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Jul-18-24 02:30AM	Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates (GlobeNewswire)
Jul-08-24 07:00AM	Pluri Announces 1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply (GlobeNewswire)
Jun-18-24 06:30AM	Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges (GlobeNewswire)
Jun-06-24 06:45AM	U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract (GlobeNewswire)
May-20-24 07:00AM	Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale (GlobeNewswire)
May-02-24 07:00AM	Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment (GlobeNewswire) +5.03%
Apr-08-24 07:00AM	Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method (GlobeNewswire)
02:52PM	Loading…
Apr-03-24 02:52PM	PLUR Stock Earnings: Pluri Reported Results for Q4 2023 (InvestorPlace) -8.70%
Mar-28-24 07:15AM	Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences (GlobeNewswire) -8.39%
Mar-27-24 07:00AM	Pluri Inc. Announces 1-for-8 Reverse Share Split (GlobeNewswire) -13.75%
Mar-21-24 07:00AM	Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report (GlobeNewswire)
Mar-19-24 04:00AM	Engage with Pluri's Talent: Exciting Conference Appearances Ahead (GlobeNewswire)
Mar-14-24 07:00AM	Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing (GlobeNewswire)
Mar-11-24 07:00AM	Pluri Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation (GlobeNewswire)
Mar-06-24 07:00AM	Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board (GlobeNewswire) +13.77%
Feb-28-24 07:00AM	Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals (GlobeNewswire)
Feb-12-24 05:20PM	Pluri: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -7.49%
Jan-23-24 02:00AM	Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis (GlobeNewswire) +15.81%
Jan-08-24 07:00AM	Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization (GlobeNewswire) -6.79%
Dec-21-23 07:00AM	Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction (GlobeNewswire)
Nov-13-23 07:29PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +5.99%
Aug-16-23 07:00AM	Pluris PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation (GlobeNewswire)
02:00AM	Loading…
Jul-13-23 02:00AM	Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors (GlobeNewswire) +5.54%
Jul-12-23 11:17AM	Deutsche Bank Predicts up to 160% Rally for These 3 Stocks Heres Why They Have Solid Upside (TipRanks) -5.25%
Jul-11-23 02:00AM	U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluris PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome (GlobeNewswire) +8.91%
Apr-27-23 07:00AM	Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products (GlobeNewswire)
Mar-13-23 08:00AM	Israels Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity (GlobeNewswire)
Dec-22-22 07:00AM	Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept (GlobeNewswire)
Dec-15-22 04:05PM	Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +9.30%
Nov-10-22 07:00AM	Pluri wins BioTech Breakthrough Cell Innovation of the Year Award (GlobeNewswire) +8.10%
Oct-31-22 08:00AM	Pluri to Present and Participate in Upcoming Conferences (GlobeNewswire)
Sep-29-22 07:00AM	Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates (GlobeNewswire)
Sep-06-22 07:00AM	7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluris PLX-PAD Cells for Osteoarthritis Treatment (GlobeNewswire)
Apr-07-22 07:00AM	Plurilock's Aurora Systems Receives US$224,000 Purchase Order from the U.S. Library of Congress (Newsfile)
Apr-01-22 07:00AM	Plurilock Names Garr Stephenson Jr. as Chief Revenue Officer (Newsfile)
Mar-31-22 07:00AM	Plurilock's Aurora Systems Receives US$1.5 Million Purchase Order from the U.S. Department of Defense (Newsfile)
Mar-28-22 07:00AM	Plurilock Submits Non-Provisional U.S. Patent Application for Multi-Device Identity Confirmation Technology (Newsfile)
Mar-23-22 07:00AM	Plurilock's Aurora Systems Receives US$1.85 Million Purchase Order from the U.S. Department of the Navy (Newsfile)
Mar-17-22 07:00AM	Plurilock Adds Brandon Swafford to Advisory Board (Newsfile)

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLUR

Pluri Inc

Upgrade your FINVIZ experience